 Heres a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks Biotech Stocks Hitting 52-week highs on Jan. 22 10X Genomics Inc NASDAQ: TXG Abbott Laboratories NYSE: ABT reported strong fourth-quarter results and issued in-line guidance Apellis Pharmaceuticals Inc NASDAQ: APLS Applied Genetic Technologies Corp NASDAQ: AGTC AtriCure Inc. NASDAQ: ATRC BIO-TECHNE Corp NASDAQ: TECH Bristol-Myers Squibb Co NYSE: BMY Cardiovascular Systems Inc NASDAQ: CSII Dr.Reddys Laboratories Ltd NYSE: RDY Eli Lilly And Co NYSE: LLY Fortress Biotech NASDAQ: FBIO Horizon Therapeutics PLC NASDAQ: HZNP received FDA nod for its thyroid eye disease drug Insulet Corporation NASDAQ: PODD Medtronic PLC NYSE: MDT Masimo Corporation NASDAQ: MASI Medpace Holdings Inc NASDAQ: MEDP Nevro Corp NYSE: NVRO Novocure Ltd NASDAQ: NVCR announced coverage in Israel for its Optune in combination with temozolomide for the treatment of newly-diagnosed glioblastoma Prevail Therapeutics Inc NASDAQ: PRVL Repligen Corporation NASDAQ: RGEN ResMed Inc. NYSE: RMD Selecta Biosciences Inc NASDAQ: SELB SI-Bone Inc NASDAQ: SIBN Soligenix, Inc. 